ERBB2 and breast cancer: Relative to older breast cancer patients, younger patients have also been characterized for a higher incidence of the more aggressive TNBC and HER2+ clinical subtypes (8, 9, 17, 18, 21–24), and a higher likelihood of harboring BRCA1/2 germ line mutations (24–26).